CREDENCE: Significant Victory for Diabetic Kidney Disease

被引：17

作者：

Verma, Ashish ^{[1
]}

Patel, Ankit B. ^{[1
]}

Upadhyay, Ashish ^{[2
]}

Waikar, Sushrut S. ^{[2
]}

机构：

[1] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA

[2] Boston Univ, Sch Med, Dept Med, Renal Sect, Boston, MA 02118 USA

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2020年 / 31卷 / 06期

关键词：

D O I：

10.1016/j.tem.2020.04.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetic kidney disease (DKD), the most common cause of end-stage kidney disease (ESKD), has significant morbidity and mortality, particularly from cardiovascular complications. The CREDENCE ( canagliflozin and renal events in diabetes with established nephropathy clinical evaluation) trial reported by Perkovic and collaborators has led to an emergence of a new class of therapeutic agents for slowing DKD progression.

引用

页码：391 / 393

页数：3

共 10 条

[1]

[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]

[2] Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside [J].

Mudaliar, Sunder ;

Polidori, David ;

Zambrowicz, Brian ;

Henry, Robert R. .

DIABETES CARE, 2015, 38 (12) :2344-2353

[3] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[4] SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action [J].

Packer, Milton .

DIABETES CARE, 2020, 43 (03) :508-511

[5] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [J].

Perkovic, V. ;

Jardine, M. J. ;

Neal, B. ;

Bompoint, S. ;

Heerspink, H. J. L. ;

Charytan, D. M. ;

Edwards, R. ;

Agarwal, R. ;

Bakris, G. ;

Bull, S. ;

Cannon, C. P. ;

Capuano, G. ;

Chu, P. -L. ;

De Zeeuw, D. ;

Greene, T. ;

Levin, A. ;

Pollock, C. ;

Wheeler, D. C. ;

Yavin, Y. ;

Zhang, H. ;

Zinman, B. ;

Meininger, G. ;

Brenner, B. M. ;

Mahaffey, K. W. ;

McGuire, Darren K. ;

Holman, Rury ;

Home, Philip ;

Scharfstein, Dan ;

Parfrey, Patrick ;

Shahinfar, Shahnaz ;

August, Phyllis ;

Chang, Tara ;

Sinha, Arjun D. ;

Januzzi, James ;

Kolansky, Daniel ;

Amerena, John ;

Hillis, Graham ;

Gorelick, Philip ;

Kissela, Brett ;

Kasner, Scott ;

Lindley, Richard ;

Fulcher, Greg ;

Ounadjela, Souhila ;

Hufert, Karina ;

von Ingersleben, Gabriele ;

Gaglia, Jason ;

Harris, Ronald ;

Hudson, Margo ;

Turchin, Alexander ;

Cheifetz, Adam .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) :2295-2306

[6] The tubular hypothesis of nephron filtration and diabetic kidney disease [J].

Vallon, Volker ;

Thomson, Scott C. .

NATURE REVIEWS NEPHROLOGY, 2020, 16 (06) :317-336

[7]

Wakisaka M, 2016, NEW ENGL J MED, V375, P1799, DOI 10.1056/NEJMc1611290

[8] Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs? Ten Years of FDA Guidance Requirements to Evaluate Cardiovascular Risk [J].

Wang, Cecilia C. Low ;

Everett, Brendan M. ;

Burman, Kenneth D. ;

Wilson, Peter W. F. .

CIRCULATION, 2019, 139 (14) :1741-1743

[9]

Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMc1902837, 10.1056/NEJMoa1812389]

[10] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].

Zelniker, Thomas A. ;

Wiviott, Stephen D. ;

Raz, Itamar ;

Im, Kyungah ;

Goodrich, Erica L. ;

Bonaca, Marc P. ;

Mosenzon, Ofri ;

Kato, Eri T. ;

Cahn, Avivit ;

Furtado, Remo H. M. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Sabatine, Marc S. .

LANCET, 2019, 393 (10166) :31-39

← 1 →